The Trump administration has reversed its decision to block Moderna's flu vaccine trial following significant pushback from the company and the broader US biotech industry. The U-turn comes after the administration initially moved to halt the clinical trial, citing unspecified concerns about the research.

Moderna, known for its COVID-19 vaccine development, had been conducting trials for its seasonal influenza vaccine candidate. The biotech sector had expressed alarm over the administration's initial decision, viewing it as potentially disruptive to ongoing medical research and development efforts. Industry groups had reportedly lobbied against the blockade.

The reversal highlights the influence of the biotechnology sector in shaping federal health policy decisions. The incident underscores the delicate balance between regulatory oversight and fostering innovation in the pharmaceutical industry. The administration's quick reversal suggests sensitivity to industry concerns about research continuity.